Clinical significance of anti-DFS70 in immunoinflammatory rheumatic diseases (review)
https://doi.org/10.47360/1995-4484-2023-100-105
Abstract
The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.
About the Authors
T. A. Panafidina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
Zh. G. Verizhnikova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
A. S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
119991, Russian Federation, Moscow, Trubetskaya str., 8, building 2
References
1. Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. doi: 10.1016/S0140-6736(13)61499-3
2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-350. doi: 10.1056/NEJM200108023450506
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928
4. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473
5. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819
6. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424
7. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al.; Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: A datadriven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-487. doi: 10.1002/acr.21591
8. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi: 10.1056/NEJMoa021933
9. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi: 10.1186/ar3258
10. Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412
11. Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128
12. Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus – what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607-614. doi: 10.1002/acr.23894
13. Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow: GEOTAR-Media;2017 (In Russ.).
14. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23. doi: 10.1136/annrheumdis-2013-203863
15. Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434-444. doi: 10.1002/art.10561
16. Aleksandrova EN, Verizhnikova ZG, Novikov AA, Lukina GV. Modern look at the problems of investigation of antinuclear antibodies in systemic lupus erythematosus (literature review). Russian Clinical Laboratory Diagnostics. 2018;63(6):340-348 (In Russ.). doi: 10.18821/0869-2084-2018-63-6-340-348
17. Kang SY, Lee WI, Kim MH, La Jeon Y. Clinical use of antiDFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423-1429. doi: 10.1007/s00296-019-04299-4
18. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized treatment. Annals of the Russian Academy of Medical Sciences. 2015;70(2):169-182 (In Russ.). doi: 10.15690/vramn.v70i2.1310
19. Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of Anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018;5:88. doi: 10.3389/fmed.2018.00088
20. Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol. 2015;6:116. doi: 10.3389/fimmu.2015.00116
21. Pisetsky DS. Antinuclear antibody testing – misunderstood or misbegotten? Nat Rev Rheumatol. 2017;13(8):495-502. doi: 10.1038/nrrheum.2017.74
22. Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and immunological dysregulation: Can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-508. doi: 10.1111/cts.12908
23. Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095-2097. doi: 10.1007/s10067-020-05180-7
24. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-1663. doi: 10.1136/annrheumdis-2020-218009
25. Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953
26. Nasonov EL, Samsonov MYu, Lila AM. Coronavirus disease 2019 (COVID-19) and autoimmunity. Annals of the Russian Academy of Sciences. 2022;92(7):654-660 (In Russ.). doi: 10.31857/S086958732207012X
27. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356. doi: 10.1155/2012/494356
28. Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-216. doi: 10.1007/s12016-016-8564-5
29. Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587-592. doi: 10.1016/s0022-5347(17)35023-1
30. Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ, et al. From autoantibody research to standardized diagnostic assays in the management of human diseases – Report of the 12th Dresden Symposium on Autoantibodies. Lupus. 2016;25(8):787-796. doi: 10.1177/0961203316644337
31. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436
32. Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412
33. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-2110. doi: 10.3899/jrheum.120598
34. Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods. 2016;436:50-53. doi: 10.1016/j.jim.2016.06.008
35. Malyavantham K, Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Autoimmun Highlights. 2017;8(1):3. doi: 10.1007/s13317-017-0091-8
36. Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32(11):2144-2149.
37. Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS70kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211-1220. doi: 10.1067/mai.2000.107039
38. Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16(3):273-293. doi: 10.1007/s10238-015-0367-0
39. Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257-266. doi: 10.1016/j.jaut.2004.07.004
40. Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14-26. doi: 10.1002/pros.20112
41. Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: Many lessons learned but still many questions. Auto Immun Highlights. 2020;11(1):3. doi: 10.1186/s13317-020-0126-4
42. Alexandrova EN, Verizhnikova ZG, Novikov AA, Panafidina TA, Popkova TV. Antibodies to DFS70 are a new biomarker for excluding the diagnosis of systemic lupus erythematosus in ANF-positive healthy individuals. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(2 Suppl 1):8 (In Russ.).
43. Aleksandrova EN, Novikov AA, Klyukvina NG, Vasiliev VI, Lukina GV. Diagnostic value of monospecifc DFS70 antibodies in systemic autoimmune rheumatic diseases. Medical Alphabet. 2021(33):38-41 (In Russ.). doi: 10.33667/2078-5631-2021-33-38-41
44. Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004;50(3):684-688. doi: 10.1002/art.20095
45. Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, et al. Clinical phenotypes of patients with antiDFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759. doi: 10.1155/2013/703759
46. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200. doi: 10.1002/art.30084
47. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900. doi: 10.1002/art.20096
48. Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, et al. Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol. 2015;42(12):2419-2426. doi: 10.3899/jrheum.150567
49. Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of antiDFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;(38):3627-3633. doi: 10.1007/s10067-019-04730-y
50. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051-1059. doi: 10.1177/0961203317692437
51. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol. 2013;40(1):92-93. doi: 10.3899/jrheum.121168
52. Infantino M, Carbone T, Manfredi M, Grossi V, Benucci M, Blank M, et al. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J. 2019;21(8):509-511.
53. Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: What’s on the horizon? Rheumatology (Oxford). 2018;57(7):1293-1298. doi: 10.1093/rheumatology/key012
54. Aljadeff G, Shemer A, Katz I, Andrade LEC, Gilburd B, Halpert G, et al. Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus. 2021;30(2):320-324. doi: 10.1177/0961203320969976
Review
For citations:
Panafidina T.A., Verizhnikova Zh.G., Avdeeva A.S., Popkova T.V., Nasonov E.L. Clinical significance of anti-DFS70 in immunoinflammatory rheumatic diseases (review). Rheumatology Science and Practice. 2023;61(1):100-105. (In Russ.) https://doi.org/10.47360/1995-4484-2023-100-105
Views:
2767
Email this article 